ClinicalTrials.gg
RecruitingNCT06781697TREASUREUpdated Oct 23, 2026

InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression

A Phase 3 interventional study of Ketamine and Oculus VR headset in Treatment Resistant Depression, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Sunnybrook Health Sciences Centre · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 23, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada — 29 open to participants now, 36 under way, 7 of them phase 3. Depressive Disorder, Treatment-Resistant · Canada.

Planned enrollment
45th of 70
31 · median 50
Started
2026
with 9 others
Phase 3
9 of 76
3 open now
Primary completion
2027-12
later than 24 of 35 live
Registered
63rd of 76
by date
Lead sponsor
8 of 76
Sunnybrook Health Sciences Centre

Among the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada, this one is the 45th largest by planned enrollment of the 70 interventional ones that give a count, is one of 10 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 24 of the 35 other live ones, and was the 63rd registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

29 of the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada, or all of them as a file.
02

Study summary

Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to begin to work and do not work at all for many people. There is therefore a need for new treatments which work quickly and effectively.

One such medication is called ketamine. Studies have shown that ketamine can treat symptoms of depression quickly. This quick action sets ketamine apart from many antidepressants that take weeks to show noticeable effects. One way that it may do this is by creating a transient sense or feeling of being separated from reality, such as seeing or hearing things that are not really there. Another way to create these same feelings is with virtual reality (VR), where a person can feel as though they are entering a 3-dimensional virtual computer-generated world by wearing a special headset or goggles with a computer inside.

In this study, all participants will receive standard ketamine treatments for depression. Half of the participants will also use a VR headset while receiving the ketamine treatments to see if ketamine and VR acting together provide a better treatment for symptoms of depression than ketamine alone.

This is a small pilot trial. The main purpose of this trial is to learn if it is possible to run a larger clinical trial comparing "ketamine and VR" with "ketamine alone", for adults with treatment-resistant depression. The researchers will study this by seeing how many participants take part in the study within 1-2 years, and how many complete the study treatments and tests. The researchers will also compare the two study groups to see if "ketamine and VR" provide a better treatment for symptoms of depression than "ketamine alone".

Read the detailed description

Depression is the single largest contributor to global disability, and afflicts individuals of all ages, races, genders, and classes. The significant morbidity is associated with depressive disorders relates to myriad direct and indirect financial costs to individuals and society. It also bears significant mortality, as one of the strongest risk factors for suicide.

Depression is also challenging to treat, with standard antidepressant therapy providing remission to only one third of patients, and incompletely improving the condition of another one third. Even when standard therapy is effective, it can take as long as six weeks for improvement of cognitive/emotional symptoms to become apparent. The final one third of patients often undergo a therapeutic odyssey in which various medications are attempted with no measurable benefit. Ultimately these patients receive a diagnosis of treatment-resistant depression (TRD).

Ketamine has emerged as a fast-acting intervention for the treatment of depressive disorders, which can reach maximum efficacy in only 24 hours and persist for 1-2 weeks. Ketamine is safe, well-tolerated, familiar to many providers and has become widely available as a treatment for depression.

Virtual reality (VR), a technology which immerses users in a controlled digital experience, has also recently been recognized for its potential in the treatment of mental health disorders and recent studies have identified similarities in proposed mechanisms for ketamine and VR in the treatment of depression (e.g. the creation of a non-ordinary and non-rigid experiences of consciousness, and the production of evocative or hallucinatory sensory experiences). However, this combination of interventions has not yet been studied.

Here, the investigators propose to study the combined effect of ketamine and VR in the vulnerable adult mental health population undergoing ketamine therapy for treatment-resistant depression (TRD).

In Phase I of the study, participants (N=3-5) will provide feedback to develop the VR software for this study population.

In Phase II, study participants (N=26) will be randomized to control (standard of care ketamine alone, Group I) or intervention (VR + ketamine concurrently (VR-K), Group II) groups to report on protocol feasibility and to inform the development of a definitive trial to assess VR-K treatment efficacy. All participants will receive a typical sub-anesthetic dose of ketamine (0.5mg/kg) infused intravenously (IV) over 45 minutes, and will be monitored by research staff for up to 90 minutes post-procedure. Each participant will receive a total of 4 ketamine treatments, 2 treatments per week for 2 weeks. All patients will continue their baseline antidepressant regimens while engaged in the study, consistent with standard ketamine therapy for TRD. Participants in the intervention group will wear a virtual reality headset at the onset of each standard ketamine therapy session, and will be immersed in a tailor-made virtual environment of positive outdoor scenes to provide relaxation and reprieve from negative thoughts.

Psychometric surveys will be used to assess the effects of both treatment arms on mood and psychiatric outcomes (depression and anxiety symptoms), side effects (sedation, dissociation, vitals), cognitive function, neural activity (EEG), and patient satisfaction with virtual reality.

03

Conditions studied

  • Treatment Resistant Depression

Keywords

  • Depression
  • Ketamine
  • Virtual Reality
  • Treatment Resistant Depression
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18, able to provide
  • Patient diagnosed with treatment-resistant depression
  • Outpatient recommended and approved by psychiatrist for ketamine treatment
  • Patients who are on IV ketamine and requiring at least 4 treatments of IV ketamine per course (prescribed by their physiatrist)
  • Cognitively alert, oriented, and able to watch immersive content and respond to questions
  • Negative human chorionic gonadotropin test before treatment, for female participants of who are not practicing medically appropriate methods of (e.g., hormonal contraceptives, implants, injectables, intrauterine devices, intrauterine systems, etc.)

Exclusion criteria

Exclusion Criteria:

  • History of psychosis/comorbid psychiatric disorders/psychotic depression/dissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist
  • Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment
  • Current or recent (within past twelve months) documented diagnosis of moderate or severe substance use disorder including uncontrolled/active alcohol abuse excepting nicotine or caffeine
  • Previous ketamine use
  • Acute dementia/delirium
  • Acute risk of suicide at baseline, as determined by the study psychiatrist
  • Pregnancy/breastfeeding
  • Previous sensitivity to ketamine or related compounds
  • Unstable medical condition which may require anesthesia consult
  • History of elevated intracranial pressure or cerebrovascular accident
  • Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction)
  • Significant motion sickness (i.e. occur during exposure to physical/visual and virtual motion, cybersickness, etc.) self-identified by patient
  • Inability to communicate with the study team
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    VR-Ketamine (VR-K)

    Participants will receive a standard course of ketamine treatment. At the onset of each ketamine therapy session, participants will be provided with an Oculus VR headset, and will be immersed in a tailor-made virtual environment of positive outdoor scenes.

    Drug: Ketamine · Device: Oculus VR headset

  • Active comparator
    Ketamine alone

    Participants will receive a standard course of ketamine treatment.

    Drug: Ketamine

Interventions

  • Standard-of-care ketamine treatment in the outpatient setting: 0.5 mg/kg IV infused over 45 minutes (with monitoring up to 90 minutes) per session, with 2 sessions per week for 2 weeks (total 4 treatments).

  • DeviceOculus VR headset

    Immersion in 45 minutes of virtual environments using the Oculus VR headset during each ketamine infusion.

06

What researchers measure

Primary outcomes

  1. Feasibility - Number of Participants who Complete at least 90% of Study Follow-ups

    The number of participants who achieve at least 90% completion of follow-ups in Phase II will be calculated.

    Time frame: From enrolment until the end of follow-ups at 3 months

  2. Feasibility - Time Required to Complete Enrolment

    The time required to enrolled to recruit 26 participants in Phase II of the pilot trial will be recorded.

    Time frame: At the time of enrolment

Secondary outcomes

  1. Mood and Psychiatric Outcomes - Montgomery-Åsberg Depression Rating Scale (MADRS)

    The MADRS is a 10-item clinician rated scale for measuring severity in the symptoms of depression. Responses for each item are measured on a scale of 0-6 (from no depressive symptomatology to severe depressive symptoms).

    Time frame: Baseline, 60 minutes and 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups

  2. Mood and Psychiatric Outcomes - General Anxiety Disorder-7 (GAD-7)

    A self-reported questionnaire measuring severity of symptoms of anxiety. The total score on the GAD-7 ranges from 0 to 21, with 0 indicating no anxiety and 21 indicating severe anxiety.

    Time frame: Baseline, 60 minutes and 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups

  3. Mood and Psychiatric Outcomes - Positive and Negative Affect Schedule (PANAS)

    Self-reported assessment of positive and negative emotions. For positive emotions, scores can range from 10-50, with higher scores representing higher levels of positive affect. For negative emotions, scores can range from 10-50, with lower scores representing lower levels of negative affect.

    Time frame: Baseline, 60 minutes and 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups

  4. Mood and Psychiatric Outcomes - Patient Health Questionnaire (PHQ-9)

    A self-reported 9-item questionnaire to assess degree of depression severity. Total scores can range from 0 to 27, with higher scores indicating more severe depression.

    Time frame: Baseline, 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups

  5. Mood and Psychiatric Outcomes - Beck Depression Inventory-II (BDI-II)

    Self-reported questionnaire about symptoms of depression, such as mood, self-dissatisfaction, guilt and fatigue. Scores range from 0 to 63, with higher scores representing higher depression severity.

    Time frame: Baseline, 24 hours after each treatment, and during 1,2,3-week and 1 and 3 month follow-ups

  6. Anti-depressant use

    The antidepressant use by participants will be collected.

    Time frame: Baseline, 1 and 3 month follow-ups

  7. Ketamine Side Effects - Heart Rate

    Heart rate will be collected before, during, and up to 60 minutes after each treatment.

    Time frame: Before, continuously during the 45-minute infusion, and up to 60 minutes after each treatment

  8. Ketamine Side Effects - Mean Arterial Pressure

    Mean arterial blood pressure will be collected before, during, and up to 60 minutes after each treatment.

    Time frame: Before, continuously during the 45-minute infusion, and up to 60 minutes after each treatment

  9. Ketamine Side Effects - Level of consciousness

    Participants' level of consciousness will be assessed using the Observer's Assessment of Alertness/Sedation Scale (OAA/S) to establish whether VR engagement is limited by ketamine's effects. The OAA/S score ranges from 1 to 5, with 1 indicating deep sleep/unconsciousness and 5 indicating alertness.

    Time frame: At baseline, once during the 45-minute infusion, and up to 60 minutes after each treatment

  10. Ketamine Side Effects - Dissociative Experiences and Psychotomimetic Side Effects

    The Clinician Administered Dissociative Symptoms Scale (CADSS-6) will be used to assess dissociative experiences and psychotomimetic side effects (i.e., hallucinations, mild depersonalization, derealization, altered time, body perception). Total scores range from 0 to 24, with higher scores indicating higher levels of dissociation.

    Time frame: At baseline, 5-10 minutes after the start of each infusion and 60 minutes after each treatment

  11. Ketamine Side Effects - Mystical Experiences Questionnaire (MEQ)

    A 30-item questionnaire for participants to self-report the degree of dissociative and hallucinogenic experiences during the treatment. Each item is scored 0-5, with 0 indicating "none" and 5 indicating "extreme."

    Time frame: 60 minutes after each treatment

  12. Ketamine Side Effects - Simulator Sickness Questionnaire

    Tolerability of the VR experience will be assessed using the Simulator Sickness Questionnaire (SSQ). Participants will rate the degree to which they experienced 16 symptoms on a scale of 0 to 3, with 0 indicating "not at all" and 3 indicating "severe."

    Time frame: At baseline and 60 minutes after each treatment

  13. Cognitive Function - tele-MoCA

    Any effect of ketamine and VR-K on cognitive function will be assessed using the telephone Montreal Cognitive Assessment (tele-MoCA). Scores range from 0 to 22, with higher scores indicating less cognitive impairment.

    Time frame: Baseline, 1 and 3 month follow-ups

  14. Change in EEG Metrics

    The effect of ketamine and VR-K on neural activity will be assessed using a Muse headband with advanced EEG brain sensors (https://ca.choosemuse.com/products/muse-2). Data will be collected using four EEG channels, two each on the anterior frontal (AF) and temporal-parietal (TP) regions, AF7, AF8, TP9, and TP10. Recordings will include data for five brainwaves: alpha, beta, delta, gamma, and theta. The change in EEG metrics will be assessed throughout each treatment and compared between the two treatment groups. Data will be collected using the Muse Lab software.

    Time frame: Before, continuously during the 45-minute infusion, and up to 60 minutes after each treatment

  15. Patient Satisfaction - System Usability Scale

    Participants in the VR-K group only will be asked to complete a VR system usability scale (VR-SUS) survey for VR technology to evaluate the ease of use of VR technology in this patient population. Participants will indicate their agreement with 8 statements on system usability on a scale of 1-5, with 1 indicating "strongly agree" and 5 indicating "strongly disagree."

    Time frame: 60 minutes after the first and final VR-K treatments

  16. Patient Satisfaction - Satisfaction Questionnaire

    A satisfaction questionnaire surveying participants' subjective thoughts on the procedure experience. The questionnaire will ask participants' level of agreement with 12 statements regarding their experience (5-level scale, from "strongly agree" to "strongly disagree"), as well as ask about participants' preferences regarding video themes/features (open-ended questions).

    Time frame: 60 minutes after the first and final VR-K treatments

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant-level data will be made available upon reasonable request to study PI following publication of full trial results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: This is a pilot trial and full inferential analysis will not be conducted until completion of the full trial. As such, data will be available following publication of the primary results of the subsequent full trial.

Access criteria: Data and supporting information will be made available following reasonable request directly to study PI.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Jan 17, 2025
StartActual
May 3, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion added, 1 removed
What changed in the criteria
Exclusion criteria
  • RemovedHistory of substance misuse and/or dependence, including chronic alcohol abuse
  • AddedCurrent or recent (within past twelve months) documented diagnosis of moderate or severe substance use disorder including uncontrolled/active alcohol abuse excepting nicotine or caffeine
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Eligibility 1 exclusion criterion added, 1 removed
    What changed in the criteria
    Exclusion criteria
    • RemovedHistory of substance misuse and/or dependence, including chronic alcohol abuse
    • AddedCurrent or recent (within past twelve months) documented diagnosis of moderate or severe substance use disorder including uncontrolled/active alcohol abuse excepting nicotine or caffeine

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06781697
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
May 3, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Fahad Alam, MD
Contact
fahad.alam@sunnybrook.ca
416-480-4864
Peter Giacobbe, MD
Contact
peter.giacobbe@sunnybrook.ca
416-480-4085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion